WuXi Biologics Congratulates Partner CANbridge Pharmaceuticals on the Approval of Innovative Velaglucerase-beta for Injection (Gaurunning) for Gaucher Disease by China NMPA

Enabled by WuXi Biologics’ industry-leading integrated technology platform, velaglucerase-beta for injection has successfully advanced from concept to commercialization.Velaglucerase-beta for injection, as the first and the only locally developed enzyme replacement therapy (ERT) for Gaucher disease in China, marks a significant…